Citadel Advisors
JANX icon

Citadel Advisors’s Janux Therapeutics JANX Stock Holding History

Citadel Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$590K Sell
38,400
-10,500
-21% -$152K ﹤0.01% 9467
2026
Q1 		$680K Buy
48,900
+1,400
+3% +$19.2K ﹤0.01% 8552
2025
Q4 		$656K Buy
47,500
+34,900
+277% +$821K ﹤0.01% 8361
2025
Q3 		$308K Buy
+12,600
New +$307K ﹤0.01% 10308
2025
Q2 		– Sell
-26,000
Closed -$702K – 13821
2025
Q1 		$702K Buy
26,000
+18,100
+229% +$682K ﹤0.01% 7741
2024
Q4 		$423K Buy
7,900
+2,600
+49% +$138K ﹤0.01% 8930
2024
Q3 		$241K Buy
5,300
+3,500
+194% +$152K ﹤0.01% 9764
2024
Q2 		$75.4K Sell
1,800
-11,800
-87% -$554K ﹤0.01% 11278
2024
Q1 		$512K Buy
13,600
+8,000
+143% +$174K ﹤0.01% 8344
2023
Q4 		$60.1K Buy
5,600
+3,200
+133% +$27.7K ﹤0.01% 11591
2023
Q3 		$24.2K Sell
2,400
-14,500
-86% -$167K ﹤0.01% 12469
2023
Q2 		$201K Sell
16,900
-35,200
-68% -$470K ﹤0.01% 9884
2023
Q1 		$630K Sell
52,100
-7,900
-13% -$131K ﹤0.01% 7824
2022
Q4 		$790K Buy
+60,000
New +$878K ﹤0.01% 7283

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Citadel Advisors's JANX Position: Q2 2026 in Review

Citadel Advisors increased its Janux Therapeutics (JANX) stake by 241% in Q2 2026, buying an estimated $12.3M and bringing the position to 1,200,737 shares worth $18.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

Citadel Advisors first reported a position in JANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $88.5M in Q1 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Citadel Advisors held 1,200,737 shares of Janux Therapeutics worth $18.4M as of Q2 2026.
  • Citadel Advisors bought 848,560 Janux Therapeutics shares in Q2 2026, an estimated $12.3M.
  • Janux Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2691 holding.
  • Citadel Advisors first reported a position in Janux Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Janux Therapeutics position peaked at $88.5M in Q1 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.